FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH

FDA Approves Expanded CRYSVITA Dosing for Adult XLH Patients

Kyowa Kirin announced on May 14, 2026, that the U.S. Food and Drug Administration (FDA) has approved a dosing update for CRYSVITA® (burosumab-twza) in adults with X-linked hypophosphatemia (XLH). This update provides healthcare providers with expanded options to individualize treatment for patients whose serum phosphorus levels are below the normal range after the initial treatment period. The new guidance allows for an increased dosage to 0.5 mg/kg, not exceeding 90 mg, every two weeks, with a potential further increase to 1 mg/kg, not exceeding 90 mg, every two weeks if needed after four weeks. This aims to support optimal patient outcomes by helping them reach and maintain normal serum phosphorus levels.

• The FDA approval introduces new, flexible dosing options for CRYSVITA, specifically for adult XLH patients whose serum phosphorus levels remain below the normal range after their initial treatment. This allows for a transition to 0.5 mg/kg every two weeks, with the possibility of further increasing to 1 mg/kg every two weeks if additional support is required after four weeks of treatment.
• This dosing update significantly enhances the ability of clinicians to provide personalized care for adults with XLH. It offers a tailored approach for patients who need more intensive management to achieve and sustain normal serum phosphorus levels, moving beyond the standard every four-week administration to optimize individual patient outcomes.
• CRYSVITA is highlighted as the only FDA-approved treatment for XLH, a rare genetic disease. Its mechanism involves a recombinant, fully human monoclonal IgG1 antibody that binds to and inhibits fibroblast growth factor 23 (FGF23), which is the root cause of hypophosphatemia in XLH, thereby restoring renal phosphorus reabsorption and increasing active vitamin D.
• The update is detailed in Section 2.3 of the full Prescribing Information for CRYSVITA, specifically addressing the Recommended Dosage for Adult Patients with X-linked Hypophosphatemia, aged 18 years and older, providing clear guidance for healthcare professionals.

The Genetic Basis and Burden of X-linked Hypophosphatemia

X-linked hypophosphatemia (XLH) is fundamentally caused by inactivating mutations in the PHEX gene (Phosphate Regulating Endopeptidase Homolog, X-Linked), which spans over 220 kb and consists of 22 exons. These mutations, including missense, nonsense, deletions, and splice site variants, follow an X-linked dominant inheritance pattern. The PHEX gene encodes a 100-105 kDa glycoprotein normally expressed in osteoblasts, osteocytes, and odontoblasts, with expression levels correlating with bone formation activity. Novel pathogenic variants continue to be identified, and mosaicism is not uncommon, requiring careful diagnostic consideration in both male and female patients presenting with heritable rickets.

The primary molecular mechanism driving XLH pathophysiology involves dysregulated fibroblast growth factor 23 (FGF23) production and metabolism. PHEX mutations lead to increased FGF23 synthesis from bone cells and reduced proteolytic cleavage of intact FGF23 protein, resulting in markedly elevated circulating levels. This excess FGF23 inhibits renal phosphate reabsorption and suppresses 1,25-dihydroxyvitamin D synthesis, creating the characteristic hypophosphatemia that defines the disorder. Studies using PHEX-knockout human induced pluripotent stem cells have confirmed that osteoblast lineage cells produce increased FGF23 and demonstrate complex intrinsic abnormalities, including enhanced CREB phosphorylation and upregulation of multiple bone matrix proteins and transcription factors.

At the cellular level, PHEX deficiency creates profound alterations in bone cell function and bone matrix mineralization. Osteoblast lineage cells from PHEX-deficient models show enhanced in vitro mineralization despite elevated extracellular pyrophosphate levels and reduced tissue non-specific alkaline phosphatase activity. The pathophysiology extends beyond bone, with FGF23 directly affecting skeletal muscle satellite cells by reducing expression of myogenic regulatory factors and muscle-specific proteins. Additionally, PHEX mutations alter cellular responsiveness to extracellular phosphate concentrations, effectively creating a lower set point for normal phosphate levels, which helps explain why standard phosphate supplementation therapy paradoxically increases FGF23 concentrations further.

Individualizing CRYSVITA Dosing for Optimal Phosphorus Control

Clinical studies of burosumab-twza have identified several key biomarkers and patient selection strategies to optimize treatment outcomes. Research has focused on baseline biochemical predictors, age-specific criteria, and comprehensive monitoring parameters to guide dosing decisions and patient management.

• Baseline serum phosphate levels serve as the primary predictive biomarker, with higher baseline phosphate predicting higher midpoint phosphate levels during treatment (p<0.05), while elevated baseline PTH (p<0.05) and FGF23 (p<0.001) were associated with lower phosphate levels at treatment midpoints

• Age-based patient selection criteria have been established, with European physicians recommending treatment initiation in children as early as 1 year of age, particularly those with profound rickets, while criteria vary from treating all children above 1 year to only those with overt rickets despite conventional therapy

• Disease severity markers guide treatment decisions, including Total Thacher rickets severity scores ≥2.0 for pediatric patients, fasting serum phosphorus <0.97 mmol/L (3.0 mg/dL), and confirmed PHEX mutations with appropriate X-linked dominant inheritance patterns

• Treatment response correlates with patient-reported outcomes, as serum phosphate exposure metrics predict disability scores, with model estimates suggesting 28%, 31%, and 25% reductions in WOMAC, brief pain inventory, and brief fatigue inventory scores respectively for each unit increase in average serum phosphate from the lower limit of normal

• Comprehensive monitoring parameters enable dose optimization, including clinical assessments (growth, deformities, bone pain), radiological evaluations (rickets severity), and biochemical markers (serum phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D, TmP/GFR ratio) for ongoing treatment guidance

• Prior conventional therapy failure serves as a key selection criterion, with patients requiring at least 6 consecutive months of conventional therapy for children younger than 3 years or 12 consecutive months for children older than 3 years before burosumab consideration

Overcoming Treatment Limitations in XLH with CRYSVITA's Update

Current treatment approaches for X-linked hypophosphatemia (XLH) face significant limitations that impact both clinical outcomes and patient quality of life. These challenges span conventional therapies, newer treatments like burosumab, and broader clinical management issues that complicate optimal care delivery.

• Conventional phosphate and vitamin D therapy limitations: Long-term complications include secondary hyperparathyroidism and renal impairment, with poor tolerability requiring multiple daily doses and complicated long-term monitoring to balance treatment benefits against potential risks

• Treatment adherence and continuity challenges: Transition from pediatric to adult services represents a particularly vulnerable period with reduced treatment adherence, greater risk of loss to follow-up, and lack of consensus regarding therapy in adults despite general agreement that all affected children should be treated

• Burosumab-specific limitations: Use in patients with chronic kidney disease has not been validated, absence of safety data necessitates discontinuation during pregnancy, and long-term follow-up studies are required to address concerns over potential nephrocalcinosis and cardiac calcification from chronic or lifelong treatment

• Persistent functional deficits: Patients often present significant functional deficits, chronic pain, and reduced quality of life despite treatment, with physical functionality more strongly associated with chronic pain and decreased muscle mass than persistent biochemical abnormalities

• Research and economic barriers: Small patient populations in trials due to disease rarity limit knowledge about rare side effects and long-term outcomes, while most drugs for rare diseases are highly expensive and lack clear indications for treatment initiation, evaluation, and duration

• Clinical management complexity: Need for multidisciplinary approaches integrating specialized sub-disciplines, with areas of limited data requiring prospective studies to define optimal management strategies for adults living with XLH

CRYSVITA's Dosing Update: A Step Towards Precision in Adult XLH

The recent FDA approval for a dosing update of CRYSVITA (burosumab-twza) in adults with X-linked hypophosphatemia (XLH) marks a pivotal moment in the management of this chronic, debilitating genetic disorder. XLH, driven by excessive fibroblast growth factor 23 (FGF23), leads to persistent hypophosphatemia and a cascade of musculoskeletal issues, including osteomalacia, fractures, and chronic pain. Burosumab, as a targeted therapy, directly neutralizes FGF23, effectively restoring phosphate homeostasis and significantly improving clinical outcomes.

This expanded dosing flexibility, allowing for titration up to 1 mg/kg every two weeks, is a strategic move towards truly individualized patient care. Studies consistently demonstrate that sustained normalization of serum phosphate levels is directly correlated with meaningful improvements in patient-reported outcomes, such as reduced pain and fatigue, enhanced physical function, and a decreased risk of fractures. By empowering healthcare providers to fine-tune dosages, this update aims to ensure more patients can achieve and maintain optimal phosphate levels, thereby maximizing therapeutic benefits and reinforcing CRYSVITA's position as the standard of care. This commitment to optimizing treatment regimens also signals a robust lifecycle management strategy, potentially informing future applications across other FGF23-mediated hypophosphatemic conditions.

However, this enhanced flexibility also underscores the need for vigilant patient monitoring. Key considerations include:

• Persistent Nephrocalcinosis: Despite burosumab's efficacy, nephrocalcinosis remains a concern, with some patients developing it even on treatment. Continued renal screening is essential, particularly given that female sex has been identified as a potential risk factor.

• Risk of Hyperphosphatemia: While aiming for normalization, aggressive dose escalation could lead to transient hyperphosphatemia, as observed in real-world settings. Careful titration and frequent biochemical monitoring are crucial to avoid this.

• Long-term Safety Profile: Although generally well-tolerated, the full long-term safety profile, especially regarding potential cardiac calcification and the lifelong impact on nephrocalcinosis, still requires further investigation.

Ultimately, this dosing update represents a significant step forward in tailoring burosumab therapy to the unique needs of adult XLH patients, promising improved quality of life and reduced disease burden, provided that careful monitoring and ongoing research continue to address the nuanced challenges of this complex condition.